A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

Patients who used GLP-1 RAs continuously for 1 year lost 5.9% of their total weight, but weight loss was still significantly greater in those who underwent bariatric surgery (22.2%). IN PRACTICE: ...

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro ...

This study analyzed 81,078 AE reports from the FAERS database, including 707 related to compounded GLP-1 RAs and 80,371 to non-compounded, FDA-approved formulations.

Since GLP-1 RAs are often prescribed to patients with obesity, this single unmeasured factor could be the true driver of the observed risk.” — Demetrios Vavvas, MD, PhD ...